These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3445023)

  • 1. Natural history of IgA nephropathy in Japan.
    Tojo S; Hatano M; Honda N; Miyahara T; Sugino N; Narita M; Sakai H
    Semin Nephrol; 1987 Dec; 7(4):386-8. PubMed ID: 3445023
    [No Abstract]   [Full Text] [Related]  

  • 2. IgA nephropathy: heterogeneous clinical pictures and steroid therapy in progressive cases.
    Kobayashi Y; Hiki Y; Fujii K; Kurokawa A; Kamiyana M; Tateno S
    Semin Nephrol; 1987 Dec; 7(4):382-5. PubMed ID: 3445022
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic indicators and treatment of childhood IgA nephropathy.
    Hogg RJ
    Contrib Nephrol; 1995; 111():194-9; discussion 199-200. PubMed ID: 7758342
    [No Abstract]   [Full Text] [Related]  

  • 4. Vasculitic IgA nephropathy: prognosis and outcome.
    Pankhurst T; Lepenies J; Nightingale P; Howie AJ; Adu D; Harper L
    Nephron Clin Pract; 2009; 112(1):c16-24. PubMed ID: 19342865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Differentiated pathogenetic therapy of glomerulonephritis].
    Belovezhdov N
    Ter Arkh; 1987; 59(8):38-40. PubMed ID: 3686444
    [No Abstract]   [Full Text] [Related]  

  • 6. [IgA nephropathy (immunoglobulin A nephropathy, M.Berger). Main symptoms: (painless) macrohematuria or microhematuria].
    Kolyvanos Naumann U; Käser L; Vetter W
    Praxis (Bern 1994); 2004 Oct; 93(44):1809-13; quiz 1814. PubMed ID: 15559904
    [No Abstract]   [Full Text] [Related]  

  • 7. [Early treatment of IgA nephritis is indicated by prognostic factors].
    Barth C
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):1009. PubMed ID: 11004913
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment tentatives in IgA nephropathy.
    Clarkson AR; Woodroffe AJ
    Semin Nephrol; 1987 Dec; 7(4):393-8. PubMed ID: 3127870
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of IgA nephropathies: a critical viewpoint].
    Mertens PR; Floege J
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):1010. PubMed ID: 11004914
    [No Abstract]   [Full Text] [Related]  

  • 10. [IgA nephropathy].
    Alamartine E
    Rev Prat; 2003 Nov; 53(18):2023-6. PubMed ID: 15008216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?
    Yoshikawa N; Ito H
    Nephrol Dial Transplant; 1999 May; 14(5):1097-9. PubMed ID: 10344344
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined immunosuppression in high-risk patients with IgA nephropathy?
    Floege J; Eitner F
    J Am Soc Nephrol; 2010 Oct; 21(10):1604-6. PubMed ID: 20829408
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of oligo-anuric forms of acute glomerulonephritis].
    Zosin C; Mănescu N
    Med Interna (Bucur); 1973 Jun; 25(6):667-76. PubMed ID: 4793938
    [No Abstract]   [Full Text] [Related]  

  • 14. IgA nephropathy in patients followed-up for at least ten years.
    Clarkson AR; Woodroffe AJ; Aarons I
    Semin Nephrol; 1987 Dec; 7(4):377-8. PubMed ID: 3445020
    [No Abstract]   [Full Text] [Related]  

  • 15. [IgA nephropathy--advances of therapy].
    Prokopiuk M; Wierzbicki P; Kade G
    Pol Arch Med Wewn; 2001 Nov; 106(5):1079-86. PubMed ID: 12026523
    [No Abstract]   [Full Text] [Related]  

  • 16. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications.
    Takemura T; Okada M; Yagi K; Kuwajima H; Yanagida H
    Pediatr Nephrol; 2002 Oct; 17(10):863-6. PubMed ID: 12376818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic findings relevant to disappearance or relapse of proteinuria following corticosteroid treatment in IgA nephropathy patients with proteinuria of 0.5 to 2.0 g/day.
    Suzuki T; Yamamoto T; Ohura M; Fujigaki Y; Yonemura K; Kimura M; Hishida A
    Clin Exp Nephrol; 2004 Sep; 8(3):243-9. PubMed ID: 15480902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Minimal-change disease with mesangial IgA deposits associated with Sjogren syndrome].
    Mon C; Sánchez Hernández R; Fernández Reyes MJ; Estébanez C; Ortiz M; Alvarez-Ude F; Mampaso F
    Nefrologia; 2002; 22(4):386-9. PubMed ID: 12369132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Randomized controlled clinical trials for IgA nephropathies].
    Yoshikawa T
    Nihon Jinzo Gakkai Shi; 2007; Suppl 50th Ann():123-9. PubMed ID: 17899839
    [No Abstract]   [Full Text] [Related]  

  • 20. The treatment of IgA nephropathy: status at the end of the millenium.
    Glassock RJ
    J Nephrol; 1999; 12(5):288-96. PubMed ID: 10630691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.